Background Renal fibrosis is a common pathological feature of the progression of chronic kidney disease. Although valproic acid (VPA) has been recently shown to induce autophagy, the effect of VPA-induced autophagy on renal fibrosis remains unknown. We, therefore, investigated whether VPA-induced autophagy suppresses renal fibrosis in a mouse model of unilateral ureteral obstruction (UUO). Methods Male C57BL/6 mice were divided into five groups (n = 8 per group): (1) sham group; (2) vehicle group; (3) VPA-treated group; (4) 3-methyladenine (3-MA; autophagy inhibitor)-treated group; and (5) VPA plus 3-MA-treated group. Mice underwent UUO and the kidneys were studied after 5 days. We also investigated the effect of VPA-induced autophagy on a-smooth muscle actin (a-SMA) in transforming growth factor (TGF)-b1-stimulated rat kidney fibroblasts and epithelial cells. Results VPA attenuated renal fibrosis and induced autophagy in UUO mice, while 3-MA increased renal fibrosis and suppressed autophagy. In addition, the anti-fibrotic effect of VPA was diminished by 3-MA in UUO mice. In rat kidney fibroblasts and epithelial cells, VPA suppressed TGF-b1-stimulated a-SMA expression and induced autophagy. In contrast, 3-MA enhanced a-SMA expression while inhibiting autophagy. Furthermore, the combined use of VPA and 3-MA treatments increased the expression of a-SMA compared with VPA treatment alone in TGF-b1-stimulated rat kidney fibroblasts and epithelial cells, which was accompanied by the inhibition of autophagy. Conclusion These findings suggest that VPA may be a candidate drug for the treatment of renal fibrosis through the induction of autophagy.
Introduction
Renal fibrosis is known as a final common pathway during the progression of chronic kidney disease (CKD), regardless of the primary disease [1] . Although a number of cytokines participate in the development of fibrosis, TGF-b1 is identified as the most important mediator in this process. Previous studies have demonstrated that TGF-b1 is responsible for multiple fibrogenic processes, including phenotype conversion of fibroblasts to myofibroblasts, proliferation of myofibroblasts, and the production of extracellular matrix proteins (ECM) [2] . However, the long-term inhibition of the TGF-b1 signaling pathway has been not established as a therapy for renal fibrosis thus far [3] .
Autophagy is a normal cellular process that is involved in the removal and recycling of bulk cytoplasmic constituents, misfolded proteins, and damaged intracellular organelles to maintain cellular homeostasis [4, 5] . Renal fibrosis is considered as a state of increased transcriptional activity of profibrotic genes, resulting in the accumulation of intracellular precursors of ECM proteins in myofibroblasts. Therefore, bulk protein degradation may show a beneficial effect on renal fibrosis [6] . In fact, previous studies have reported that autophagy is induced in a mouse model of renal fibrosis and that pharmacological inhibition of autophagy intensifies renal fibrosis [7, 8] . These findings raise the possibility that enhanced autophagy may be a therapeutic target.
Valproic acid (VPA) has been used clinically in the treatment of epilepsy, bipolar disorder, and prevention of migraine headaches. Notably, VPA is metabolized in the liver and its safety is well known even in the CKD patients by monitoring blood levels. Recently, VPA was identified as a histone deacetylase (HDAC) inhibitor and has been shown to induce autophagy [9] [10] [11] , leading us to the hypothesis that VPA improves renal fibrosis through the induction of autophagy.
In this study, we have demonstrated that VPA induces autophagy and suppresses renal fibrosis in mice with unilateral ureteral obstruction (UUO). We also showed that inhibition of autophagy by 3-methyladenine (3-MA) intensified renal fibrosis and that the combined therapy eliminates both the beneficial effect of VPA and detrimental effect of 3-MA on renal fibrosis in UUO mice. Furthermore, we have presented that VPA inhibits TGFb1-induced myofibroblastic changes through the induction of autophagy. These results suggest that VPA-enhanced autophagy confers the ability to suppress renal fibrosis.
Materials and methods

Animals
Male C57BL/6 mice (7-8 weeks of age) that weighed 20-26 g were purchased from Charles River Laboratories Japan (Yokohama, Japan) and had free access to the standard food and water. The Institutional Animal Care and Use Committee at Hiroshima University (Hiroshima, Japan) approved all the animal protocols, and the experiments were performed in accordance with the National Institutes of Health Guidelines on the Use of Laboratory Animals. After intraperitoneal injection of pentobarbital sodium (50 mg/ kg), UUO was performed by ligation of the left ureter twice with 4-0 suture silk through a left flank incision. A control group of mice were subjected to sham operations that were identical to the ones performed on mice with UUO, with the exception that the ureters were not ligated. Mice were killed on day 5 after UUO and renal tissue harvested.
Drug administration in mice
VPA was kindly provided by Kyowa Hakko Kirin Co. (Tokyo, Japan). 3-MA, an autophagy inhibitor, was purchased from Sigma-Aldrich (St. Louis, MO, USA). VPA and 3-MA were dissolved in normal saline and injected intraperitoneally once a day for 5 days. The mice were divided into five groups (n = 8 per group): (1) sham mice receiving normal saline (sham group); (2) UUO mice receiving normal saline (vehicle group); (3) UUO mice receiving VPA (VPA-treated group, 100 mg/kg/day); (4) UUO mice receiving 3-MA (3-MA-treated group, 50 mg/ kg/day); and (5) UUO mice receiving both VPA and 3-MA (VPA plus 3MA-treated group, VPA 100 mg/kg/day plus 3-MA 50 mg/kg/day).
Cell culture and treatment
The rat kidney fibroblast cell line NRK-49F and rat epithelial cell line NRK-52E were obtained from the American-Type Culture Collection (Manassas, VA, USA) and cultured as described previously [12] . These cells were grown to 70-80% confluency, washed twice with phosphate-buffered saline (PBS), and starved for 24 h in 0.1% FBS medium before being used for the experiments. VPA was used as an autophagy inducer, and 3-MA was used as an inhibitor of autophagy. VPA and 3-MA were dissolved in PBS to make 1 M and 100 mM stock solutions, respectively, and stored at room temperature.
Pre-incubation of VPA and/or 3-MA was carried out 30 min before human recombinant TGF-b1 (R&D Systems, Minneapolis, MN, USA) stimulation. The cells were divided into four groups: (1) control; (2) VPA (10 mM); and (3, 4) combined treatment of VPA and 3-MA (5 or 10 mM) groups. After 6-8 h, proteins of the cultured cells were extracted from dishes for analysis.
Western blot analysis
Western blotting was performed as described previously [13, 14] . The primary antibodies used were as follows: anti-LC3-I and LC3-II antibody (Cell Signaling Technology, Danvers, MA, USA), anti-Beclin1 antibody (Cell Signaling Technology), anti-a-SMA antibody (SigmaAldrich), and anti-a-tubulin antibody (Sigma-Aldrich). The secondary antibodies used were polyclonal goat anti-mouse or rabbit immunoglobulins/HRP (Dako, Glostrup, Denmark), diluted 1:5000, and incubated for 1 h in room temperature. Antibody binding was enhanced with SuperSignal West TM , Pico TM or Dura TM , Chemiluminescent Substrate (Thermo Fisher Scientific, Rockford, IL, USA). The intensity of each band was quantified by densitometry using the ImageJ software (version 1.46r; National Institutes of Health, Bethesda, MD, USA).
Histological analysis and immunohistochemistry
Bilateral kidneys from each mouse were fixed in 10% neutral buffered formalin for 4 h at room temperature then embedded in paraffin. For light microscopy, Masson's trichrome staining and the immunolabeling were performed on the sections from paraffin embedded preparation (4-lm thickness) using methods described previously in detail [15] . The following primary antibodies were used: anti-a-SMA antibody (Sigma-Aldrich) and anti-collagen-1 antibody (Abcam, Cambridge, MA, USA). The images were acquired and analyzed by the NIS Element software with Nikon microscope image system (Tokyo, Japan).
Statistical analyses
Data from histological, immunohistochemical, and western blot analysis are expressed as the mean ± standard deviation. Statistical analysis was performed using analysis of variance (ANOVA) followed by Tukey's post hoc test. A P value of P \ 0.05 was considered statistically significant.
Results
VPA ameliorated interstitial connective tissue in UUO mice
To evaluate the effect of VPA on connective tissue in UUO mice, we performed Masson's trichrome staining. Histological analysis confirmed that, compared with normal kidney (Fig. 1a) , VPA attenuated UUO-induced renal fibrosis (Fig. 1b, c) , whereas 3-MA alone worsened the fibrosis ( deleterious effect of 3-MA in UUO mice (Fig. 1e) . Quantification of staining in renal tissue is shown in Fig. 1f .
VPA suppressed the interstitial expression of a-SMA in UUO mice
Transdifferentiation of renal fibroblasts and epithelial cells to myofibroblasts is an important process in renal fibrosis and a-SMA is the molecular hallmark of myofibroblasts. We, therefore, examined expression of a-SMA in whole kidneys in UUO mice. The expression of a-SMA was increased after UUO and its expression decreased with VPA treatment. Although 3-MA administration showed b Fig. 2 VPA suppresses a-SMA expression in UUO mice, but 3-MA enhances it. a Representative western blotting analysis for a-SMA in mice with UUO on day 5. UUO mice were treated with VPA (100 mg/kg/day) or 3-MA (50 mg/kg/day) or both. a-Tubulin was used as an internal control. b Quantification of western blotting demonstrating the effect of VPA or 3-MA or both on a-SMA in UUO mice on day 5. The intensity of bands was normalized to a-tubulin. upregulation of a-SMA expression, the combination of VPA and 3-MA did not shows a significant difference compared with the vehicle control (Fig. 2a, b) . Immunohistochemical staining also revealed that a-SMA was expressed in the renal arterioles, but it was rarely evident in the interstitium of normal kidneys (Fig. 2c) . UUO induced a marked increase in the a-SMA-positive area in the vehicle group (Fig. 2d) . VPA administration attenuated UUO-induced a-SMA expression (Fig. 2e) , whereas 3-MA treatment resulted in a further increase in interstitial a-SMA expression compared with the vehicle control (Fig. 2f) . In addition, the combined use of VPA and 3-MA reduced interstitial expression of a-SMA compared with 3-MA alone at 5 days after UUO (Fig. 2g) . The quantification of immunostaining in renal tissue is shown in Fig. 2h .
VPA suppressed the interstitial expression of collagen-1 in UUO
The accumulation of ECM proteins is a crucial process in tubulointerstitial fibrosis. Because collagen-1 is a major component of the ECM [16] , we assessed immunohistochemical staining for collagen-1. Collagen-1 positive area was observed in the renal arterioles, but the expression was rarely evident in the interstitium of normal kidneys (Fig. 3a) . UUO induced collagen-1 expression in the tubulointerstitial area (Fig. 3b) . In contrast, VPA attenuated increased expression of collagen-1 (Fig. 3c) , whereas 3-MA intensified collagen-1 expression compared with the vehicle group (Fig. 3d) . In addition, the combined use of VPA and 3-MA reduced the expression of collagen-1 compared with 3-MA alone in treated mice at 5 days after UUO (Fig. 3e) . Quantification of immunostaining in renal tissue is shown in Fig. 3f .
VPA increased the LC3-II/LC3-I ratio in UUO mice, but 3-MA suppressed VPA-induced autophagy
During the progression of autophagy, the cytosolic form of microtubule-associated protein 1A/1B-light chain 3-I (LC3-I) is converted to LC3-II, and thereby the LC3-II/ LC3-I ratio reflects autophagy activity. To determine the effect of VPA and 3-MA on autophagy, we performed western blot analysis for LC3-I and LC3-II. UUO increases the LC3-II/LC3-I ratio, and a further increase was observed in UUO mice with VPA treatment. In contrast, 3-MA treatment decreased the LC3-II/LC3-I ratio to the same level as the vehicle group, and combination therapy of VPA and 3-MA decreased the LC3-II/LC3-I ratio compared with that in UUO with VPA treatment (Fig. 4a) . Quantification is shown in Fig. 4b .
VPA suppressed TGF-b1-induced myofibroblastic changes in NRK-49F and NRK-52E cells TGF-b1-induced myofibroblastic changes play an essential role in the development of renal fibrosis [17] . To examine effect of VPA and 3-MA on the expression of a-SMA, we studied TGF-b1-induced a-SMA expression in NRK-49F and NRK-52E cells. The expression levels of a-SMA were significantly increased at 8 h after TGF-b1 treatment in NRK-49F (Fig. 5a ) and NRK-52E (Fig. 5c ) cells. VPA treatment suppressed a-SMA expression at 8 h, whereas 3-MA enhanced it. Moreover, the combined use of VPA and 3-MA treatments increased the expression of a-SMA compared with VPA treatment alone in TGF-b1-stimulated NRK-49F and NRK-52E cells. Quantification is shown in Fig. 5b and d. VPA promoted and 3-MA suppressed autophagy in TGF-b1-stimulated NRK-49F and NRK-52E cells TGF-b1 reportedly induces not only ECM protein expression [18] , but also autophagy [19, 20] . Because myofibroblasts are a major source of ECM proteins, we In addition, Beclin1 (also called Atg6), a key regulator of autophagy, forms a complex with Vps34, the class III phosphatidylinositol 3-kinase, as a first step for autophagy initiation. Similar to LC3 conversion, Beclin1 expression was suppressed by TGF-b1 stimulation, whereas it was increased by VPA treatment. Combination therapy also diminished the effect of VPA on Beclin1 expression in a dose-dependent manner (Fig. 7a, b, c and d ).
Discussion
In this study, we have demonstrated that UUO induces autophagy and a further increase is observed after VPA administration. Although VPA suppresses renal fibrosis in UUO mice, inhibition of autophagy by 3-MA diminished the anti-fibrotic effect of VPA. Furthermore, we show that VPA suppresses TGF-b1-induced a-SMA expression, along with increased autophagy markers, such as the LC3 II/I ratio and Belin 1, in rat renal fibroblast and epithelial cell lines. In the in vitro study, 3-MA attenuated the beneficial effect of VPA on a-SMA expression, as well as expression of autophagy markers. These findings suggest that the induction of autophagy by VPA is a novel therapeutic option for renal fibrosis.
Clinically, VPA increases levels of gamma-aminobutyric acid and dopamine and promotes serotonin metabolism; therefore, it is currently used as an anti-epilepsy, antimelancholy, and anti-migraine drug. Although its clinical effectiveness and safety have been established, the pharmaceutical action of VPA has been not fully elucidated.
Recently, VPA was recognized as an inhibitor of class I HDACs [10, 11] , indicating that HDAC inhibitors are promising new therapeutic compounds for fibrotic diseases.
In fact, HDAC inhibitors have already shown beneficial effects on fibrosis [21, 22] . However, inhibition of histone deacetylation promotes transcriptional activity, and therefore, the anti-fibrotic effects of VPA cannot be explained only by the pharmacological action for histone modification.
A previous study clarified that HDAC inhibitors confer the ability to induce autophagy through inhibition of the mammalian target of rapamycin (mTOR) pathway [23] . A recent study has also reported that VPA induces autophagy by suppression of the mTOR pathway [24] . In this study, VPA improved renal fibrosis along with increased markers of autophagy, whereas inhibition of autophagy worsened renal fibrosis. Renal fibrosis is recognized to be a state of over-production of ECM protein [25, 26] , indicating that autophagy-mediated degradation of ECM proteins would be one therapeutic option that potentially inhibits renal fibrosis.
We have also demonstrated that TGF-b1 induces transdifferentiation to a-SMA-positive myofibroblasts in vitro. Among renal cells, resident fibroblast cells in the tubulointerstitial space are a major source of a-SMA-positive myofibroblasts [25] , contributing to ECM protein production. In this study, we have shown that inhibition of autophagy with the use of 3-MA results in increased expression of a-SMA in renal myofibroblasts and epithelial cells as well as in UUO mice. Our resulting data imply that autophagy confers the ability to suppress TGF-b1-mediated transdifferentiation. Moreover, enhanced autophagy reportedly regulates TGF-b1 expression [27] , leading to decreased renal fibrosis in UUO mice. Past studies also showed the beneficial effects of autophagy on aging, tubular cell death, and hypoxia-related tubular damage [28] [29] [30] [31] . Taken together, this suggests that autophagy performs its anti-fibrotic functions through various mechanisms.
In addition to its renoprotective effects, autophagy principally serves an adaptive role to protect organs against diverse pathologies, including infections, cancer, neurodegeneration, aging, and heart diseases [32] . However, autophagy has dual roles in cancer, acting not only as a tumor suppressor by preventing the accumulation of damaged proteins and organelles, but also as a mechanism of cell survival that can promote the growth of established tumors. In the case of fibrosis, it has also been reported that autophagy can upregulate [33] and downregulate [29, 34] the fibrotic process in different cell lines. Although our data suggest that autophagy may protect against renal fibrosis, its clinical application should be undertaken with great caution.
In conclusion, our present results support that autophagy induced by VPA has a renoprotective role in both the obstructed kidney and TGF-b1-stimulated NRK-49F and NRK-52E cells. Previous studies suggest that VPA attenuates renal fibrosis through various mechanisms. However, because 3-MA erases the beneficial effect of VPA on renal fibrosis in vivo and in vitro, VPA-induced autophagy is likely to play an important role in the suppression of renal fibrosis. These findings indicate that VPA may be a candidate drug for the treatment of renal fibrosis, and give additional information to understand the mechanism between renal fibrosis and autophagy. Fig. 7 VPA increases Beclin1 in TGF-b1-stimulated NRK-49F and NRK-52E cells, but 3-MA decreases it. a Typical western blotting analysis for Beclin1 in TGF-b1-stimulated NRK-49F cells. Pretreatment of VPA (10 mM) and/or 3-MA (5 or 10 mM) was conducted 60 min before TGF-b1 stimulation (1 ng/mL). a-Tubulin was used as an internal control. b Quantification of western blotting demonstrating the effect of VPA or 3-MA or both on Beclin1 in TGF-b1-stimulated NRK-49F cells. c Typical western blot analysis of Beclin1 in TGFb1-stimulated NRK-52E cells. Pretreatment with VPA (10 mM) and/ or 3-MA (5 or 10 mM) was conducted at 60 min before TGF-b1 stimulation (3 ng/mL). a-Tubulin was used as an internal control. d Quantification of western blotting, demonstrating the effect of VPA, 3-MA, or both on Beclin1 in TGF-b1-stimulated NRK-52E cells. The intensity of bands was normalized to a-tubulin. Data are mean ± SD. ***P \ 0.001, n = 6 samples per group
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